1. Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: Case series
- Author
-
Tugce Sarikaya, Rehile Zengin, Nazire Afsar, Dilaver Kaya, Ibrahim Ozkan Akinci, Lerzan Dogan, Alp Dinçer, and Acibadem University Dspace
- Subjects
0301 basic medicine ,Male ,Pediatrics ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.medical_treatment ,Pneumonia, Viral ,Immunology ,macromolecular substances ,Article ,law.invention ,Autoimmune Diseases ,03 medical and health sciences ,Betacoronavirus ,Behavioral Neuroscience ,0302 clinical medicine ,law ,Meningoencephalitis ,Pandemic ,medicine ,Humans ,Pandemics ,business.industry ,SARS-CoV-2 ,Endocrine and Autonomic Systems ,Mortality rate ,COVID-19 ,Plasmapheresis ,Middle Aged ,medicine.disease ,Intensive care unit ,030104 developmental biology ,Encephalitis ,Female ,business ,Coronavirus Infections ,030217 neurology & neurosurgery ,Autoimmune - Abstract
Highlights. • Severely ill COVID-19 patients failing to regain consciousness or showing agitation during the ventilation weaning period require thorough neurological assessment. • Brain magnetic resonance imaging and cerebrospinal fluid examination are required to determine the extent of central nervous system involvement. • Neurological involvement during COVID-19 infection can be immune mediated. • Plasmapheresis can be beneficial in COVID-19 patients with autoimmune encephalitis., Severe SARS-CoV-2 (COVID-19) infection has the potential for a high mortality rate. In this paper, we report the results of plasmapheresis treatment in a series of severely ill patients with COVID-19–related autoimmune meningoencephalitis in the Intensive Care Unit ICU.
- Published
- 2020